|Bid||2.1600 x 1100|
|Ask||2.1800 x 1100|
|Day's Range||2.1400 - 2.2200|
|52 Week Range||1.6500 - 3.7800|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.70|
Subscribe to Yahoo Finance Plus to view Fair Value for OVID
The big shareholder groups in Ovid Therapeutics Inc. ( NASDAQ:OVID ) have power over the company. Institutions will...
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two leading epilepsy research meetings Ended the second quarter 2022 with cash, cash equivalents and marketable securities of $152.4 million, expected to support the advancement of its epilepsy pipeline into 2025 NEW YORK, Au
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...